Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 543

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 543
---
 | ​ | ​ | ​            | ​ |  1,000 | ​ | ​ | ​ | ​    | ​ |      — | ​ | ​ |
| Short-term debt, related parties | ​ | ​ | ​                                     | ​ | ​ | ​            | $ | 16,050 | ​ | ​ | ​ | ​    | $ | 16,500 | ​ | ​ |

As of December 31, 2023 and 2022, the Company’s outstanding debt agreements are all classified as current as the Feelux Bonds, Cart-Tcelkor, Valetudo Loan, Ewon Loan, and the Valetudo June 2023 Loans are past due and the remaining debt agreements are due within one year. The Feelux Bonds, the Car-Tcellkor Loan, the Ewon Loan, the Valetudo Loan, the Valetudo June 2023 Loans, the Valetudo July 2023 Loan, the Valetudo August 2023 Loans, the Ewon September 2023 Loan, the Valetudo November 2023 Loan, and the Ewon December 2023 Loan are with related parties (see Note 4). The TDT Loan — CAR-T products and TDT Loan — Vaccine Products are related to the CAR-T License and the Vaccine License, respectively (see Note 3). In May 2022, the Company entered into a term note for $1.4 million with Ziebel, LLC, a related party of the Company, that bears interest at 3% and was due in July 2022. The note and interest were repaid in July 2022. In May 2022, the Company borrowed $2.3 million from a party that was not a related party of the Company during the year ended December 31, 2022. The loan does not bear interest and was repaid in July 2022. Note 6. Members’ Deficit In May 2022, the Company issued 8.4 million new Class A member units for $4.2 million, or $0.50 per unit. In December 2022, in conjunction with the Valetudo Loans (see Note 4), the Company repurchased 1.4 million of the Class A member units for $0.7 million, or $0.50 per unit. On May 20, 2018, the Company issued 10,000,000 Class A member units for $0.1